Corneal features in trastuzumab emtansine treatment: not a rare occurrence

Antibody–Drug Conjugates for Cancer Treatment

(2018) John M. Lambert et al.   Annual Review of Medicine

Corneal Changes in Trastuzumab Emtansine Treatment

(2018) Elke O. Kreps et al.   Clinical Breast Cancer

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

(2017) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

Drug-induced corneal epithelial changes

(2017) Michael B. Raizman et al.   SURVEY OF OPHTHALMOLOGY

Abnormal Corneal Lesions Induced by Trastuzumab Emtansine

(2016) Mayuko Tsuda et al.   CORNEA

New developments for antibody-drug conjugate-based therapeutic approaches

(2016) Bart ECG de Goeij et al.   CURRENT OPINION IN IMMUNOLOGY

Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy

(2016) Taleen V. Jerjian et al.   PHARMACOTHERAPY

Trastuzumab-induced corneal ulceration: successful no-drug treatment of a “blind” side effect in a case report

(2015) A. Orlandi et al.   BMC CANCER

Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials

(2015) Joshua Seth Eaton et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS